Roche Holding AG/€ROG
05:30
15:10
00:45
10:25
20:00
1D1W1MYTD1Y5YMAX
About Roche Holding AG
Roche Holding AG is a Swiss multinational healthcare company based in Basel, Switzerland, specializing in pharmaceuticals and diagnostics. The company's pharmaceutical division is renowned for developing innovative medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche's diagnostics segment offers products and services for research and medical applications, including in vitro diagnostics and instruments for hospitals, labs, and physicians. Founded in 1896, Roche has a significant global presence, operating in numerous countries worldwide. The company is strategically positioned through its focus on personalized healthcare, leveraging its expertise in both pharmaceuticals and diagnostics to deliver tailored treatment solutions.
Ticker
€ROG
Sector
Primary listing
XGAT
Employees
103,249
Headquarters
Basel, Switzerland
Website
Roche Holding AG Metrics
BasicAdvanced
€243B
22.56
€12.57
0.17
€10.14
3.57%
Price and volume
Market cap
€243B
Beta
0.17
52-week high
€326.58
52-week low
€247.15
Average daily volume
75K
Dividend rate
€10.14
Financial strength
Current ratio
1.294
Quick ratio
0.884
Long term debt to equity
84.935
Total debt to equity
104.809
Dividend payout ratio (TTM)
81.99%
Interest coverage (TTM)
16.47%
Profitability
EBITDA (TTM)
25,077.699
Gross margin (TTM)
74.79%
Net profit margin (TTM)
14.85%
Operating margin (TTM)
31.94%
Effective tax rate (TTM)
21.55%
Revenue per employee (TTM)
€652,920
Management effectiveness
Return on assets (TTM)
13.30%
Return on equity (TTM)
31.32%
Valuation
Price to earnings (TTM)
22.561
Price to revenue (TTM)
3.324
Price to book
7.42
Price to tangible book (TTM)
48.99
Price to free cash flow (TTM)
15.977
Free cash flow yield (TTM)
6.26%
Free cash flow per share (TTM)
17.751
Dividend yield (TTM)
3.57%
Forward dividend yield
3.57%
Growth
Revenue change (TTM)
4.80%
Earnings per share change (TTM)
-11.28%
3-year revenue growth (CAGR)
-2.08%
10-year revenue growth (CAGR)
2.35%
3-year earnings per share growth (CAGR)
-12.59%
10-year earnings per share growth (CAGR)
1.24%
3-year dividend per share growth (CAGR)
1.41%
10-year dividend per share growth (CAGR)
1.95%
Bulls say / Bears say
Roche reported a 6% increase in core operating profit to CHF12.0 billion in H1 2025 (11% at constant exchange rates), driven by cost management and strong demand for Phesgo and Xolair while maintaining full-year earnings guidance. (Reuters)
Revenues of the breast cancer drug Phesgo jumped 55% to CHF1.2 billion and allergy treatment Xolair rose 34% to CHF1.45 billion in H1 2025, both beating forecasts and underpinning Roche’s pharmaceutical division growth. (Reuters)
Roche has initiated a late-stage prevention trial of trontinemab in high-risk individuals to delay or prevent Alzheimer’s symptoms, leveraging novel brain shuttle technology to bolster its neuroscience pipeline. (Reuters)
Roche voluntarily paused shipments of its Duchenne muscular dystrophy gene therapy Elevidys outside the U.S. after a third patient’s death from acute liver failure, potentially delaying global commercialization and tarnishing safety perception. (Reuters)
The diagnostics division’s sales remained flat at CHF7.0 billion in H1 2025 as gains in pathology and blood screening tests merely offset adverse healthcare pricing reforms in China, constraining revenue diversification. (Reuters)
The appreciation of the Swiss franc against the U.S. dollar weighed on reported H1 2025 results, reducing the reported value of international sales and posing a persistent currency headwind. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roche Holding AG stock?
Roche Holding AG (ROG) has a market cap of €243B as of September 15, 2025.
What is the P/E ratio for Roche Holding AG stock?
The price to earnings (P/E) ratio for Roche Holding AG (ROG) stock is 22.56 as of September 15, 2025.
Does Roche Holding AG stock pay dividends?
Yes, the Roche Holding AG (ROG) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €10.13635 and the yield is 3.57%. Roche Holding AG has a payout ratio of 81.99% on a trailing twelve-month basis.
When is the next Roche Holding AG dividend payment date?
The next Roche Holding AG (ROG) dividend payment date is unconfirmed.
What is the beta indicator for Roche Holding AG?
Roche Holding AG (ROG) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.